Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare...( Wound Care Centers - Chronic wounds r...),Health

Date:8/27/2009

>Wound Care Centers - Chronic wounds represent a significant unmet medical need as evidenced by the emergence and growth of wound care centers across the U.S. These centers were developed by healthcare providers to provide specialized treatment to chronic wound patients. There are an estimated 1,000 outpatient wound care centers across the U.S. Wound care centers offer a broad spectrum of specialized care as well as best clinical practices for managing wound healing. Many centers provide hyperbaric oxygen therapy and most have access to a multidisciplinary medical team. Usually associated with a hospital, these centers provide a focused approach to wound management with the goal of reducing the need for inpatient care and surgical procedures such as amputation.

Excellarate Product Candidate - Cardium's Excellarate product candidate is initially being developed to facilitate wound closure in non-healing diabetic foot ulcers. The Company believes that the ability to achieve closure of chronic, non-healing wounds following the treatment of a simple-to-use, physician administrated topical gel offers the potential for considerable benefit to patient populations with chronic diseases such as diabetes. Currently available advanced wound care products for these patients have a number of limitations such as requiring a regimen of repeated wound cleanings and product re-administrations, multiple trips to a treatment center, or custom-produced and expensive skin substitutes. In addition, many patients, including approximately one in seven participants in the MATRIX clinical study, have wounds that do not close even after previous treatment with what are regarded as the most advanced wound care therapies currently available (i.e., repeat-administration therapies using becaplermin protein or negative pressure pumps, or "living-skin" equivalents).

Market Opportunity and Pharmaco
'/>"/>

SOURCE Cardium Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
2. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
3. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
4. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
5. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
6. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
7. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
8. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
9. Wyoming Department of Healths Pay-for-Participation Program Reports Positive Clinical Outcomes
10. Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
11. Nektar Therapeutics Reports Second Quarter 2009 Financial Results